Monte Rosa Therapeutics, Inc.

GLUE·NasdaqGS·Healthcare
Compare
10.52+0.22 (+2.14%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours10.520.00 (0.00%)Oct 12, 5:30 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close10.30
Open10.29
Day range10.1410.63
52-week range8.9425.77
Off day high−1.03%
Off 52-week high−59.18%
Volume1.83M
Avg. volume (3M)1.32M
Market cap897.50M
EPS (TTM)-1.75
Forward P/E-5.40
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)1.37
Shares outstanding85.31M
Short interest23.44% of float
Earnings dateAug 6, 2026 (est.)
Analyst target26.88
Profit margin0.00%

Against its peers

Compare in full ›
GLUE CCCC KYMR ARVN NRIX OLMA
Market cap 897.50M 376.46M 9.22B 480.68M 2.30B 643.98M
P/E (TTM) — — — 28.7 — —
Forward P/E -5.4 -3.2 -22.0 -2.3 -20.8 -2.8
Price/book 1.8 1.5 6.1 0.9 5.7 1.5
Dividend yield — — — — — —
1-year change −0.96% +51.49% +87.68% −20.83% +129.94% −27.26%
Today +2.14% −3.16% −0.28% −2.49% −0.85% −5.88%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All GLUE news ›
@StockTitan_net·

Monte Rosa Therapeutics officer sells 13 shares

Monte Rosa Therapeutics (GLUE) is a clinical-stage biotech developing molecular glue degrader medicines for oncology, autoimmune, inflammatory and cardiovascular diseases. - [Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity…

MarketBeat·Positive

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study

Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study…

Seeking Alpha·Positive

Monte Rosa posts trial data for anti-inflammatory drug (GLUE)

Seeking Alpha Monte Rosa Therapeutics (GLUE) traded higher in premarket after the company announced plans to begin multiple Phase 2 trials for its anti-inflammatory agent MRT-8102 following encouraging results from a Phase 1 study. The…

From articles in the 4Search news index.

In the news

9mentions in 30 days
7with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.